Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
Earnings Data
Report Date
Nov 05, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.04Last Year’s EPS
-0.02Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a strong quarter for Amicus Therapeutics with significant revenue growth and strategic advancements, particularly in Galafold and Pombiliti/Opfolda sales. Despite increased operating expenses and a decline in non-GAAP net income, the company's positive revenue trajectory, successful product launches, and advancements in their strategic partnership with Dimerix for DMX-200 highlight a positive outlook.Company Guidance
Double-Digit Revenue Growth
Amicus delivered its 17th consecutive quarter of double-digit revenue growth at constant exchange rates, with a 22% increase in total revenue to $154.7 million over the same period in 2024.
Strong Galafold Performance
Galafold revenue reached $128.9 million this quarter, up 12% at constant exchange rates and 16% in reported terms, ending the quarter with over 69% global market share for treated Fabry patients with amenable mutations.
Pombiliti and Opfolda Sales Growth
Revenue for Pombiliti and Opfolda reached $25.8 million, up 58% at constant exchange rates, with strong sales growth driven by new launches in several countries.
Positive Financial Outlook
The company reiterated its expectation to achieve positive GAAP net income during the second half of 2025, reflecting strong financial discipline.
Advancement of DMX-200
The strategic partnership with Dimerix for DMX-200 in late-stage Phase III development for a rare kidney disease marked a key milestone with the ACTION3 pivotal study on track for full enrollment by year-end.
FOLD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FOLD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 31, 2025 | $6.13 | $5.99 | -2.28% |
May 01, 2025 | $7.68 | $6.68 | -13.02% |
Feb 19, 2025 | $9.85 | $9.56 | -2.94% |
Nov 06, 2024 | $11.74 | $11.24 | -4.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amicus Therapeutics (FOLD) report earnings?
Amicus Therapeutics (FOLD) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).
What is Amicus Therapeutics (FOLD) earnings time?
Amicus Therapeutics (FOLD) earnings time is at Nov 05, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FOLD EPS forecast?
FOLD EPS forecast for the fiscal quarter 2025 (Q3) is 0.04.